Daniel Lee Flynn - Dec 15, 2021 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role: Chief Scientific Officer
Signature: /s/ Jeffrey Held, Attorney-in-Fact
Stock symbol: DCPH
Transactions as of: Dec 15, 2021
Transactions value $: $0
Form type: 4
Date filed: 12/17/2021, 03:00 PM
Next filing: Jan 20, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DCPH	Common Stock	Award	$0	+11.1K	+62.95%	$0.00	28.7K	Dec 15, 2021	Direct	F1
holding	DCPH	Common Stock						230K	Dec 15, 2021	By Daniel L. Flynn Revocable Trust
holding	DCPH	Common Stock						91K	Dec 15, 2021	By Daniel L. Flynn Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DCPH	Stock Option (Right to Buy)	Award	$0	+82.3K		$0.00	82.3K	Dec 15, 2021	Common Stock	82.3K	$9.23	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person was awarded 11,100 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2	This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date.

Content

The reporting person was awarded 11,100 Restricted Stock Units ("RSUs") under the Issuer's 2017 Stock Option and Incentive Plan (the "2017 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

This stock option was issued pursuant to the 2017 Plan. The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date.